NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. Marielle Cohard-Radice
Daiichi Sankyo Announces Global Head of Development
Daiichi Sankyo has appointed Marielle Cohard-Radice, M.D. as executive VP, global head of development.
In this new role, Dr. Cohard-Radice reports to Glenn Gormley, M.D., Ph.D., senior executive officer and global head, research and development, Daiichi Sankyo Co., and chairman of the board and president, Daiichi Sankyo. She has responsibility for the development strategy and portfolio planning for the cardiovascular-metabolism and internal medicine therapeutic areas. She is responsible for supporting the oncology clinical development group.
Prior to her promotion, Dr. Cohard-Radice was VP of clinical development operations at Daiichi Sankyo Pharma Development, a position she has held since 2012.
She earned her M.D. from the Université Joseph Fourier (Grenoble I), specializing in gastroenterology. She also holds a diploma in Medical Applications of Statistics from the Université Pierre et Marie Curie (Paris VI).
Dr. Levi Garraway
Lilly Appoints Senior VP of Oncology
Eli Lilly and Company has appointed Levi Garraway, M.D., Ph.D., senior VP, global development and medical affairs, for Lilly’s Oncology business on January 1, 2017. He succeeds Richard Gaynor, M.D., who is retiring after a distinguished career at Lilly.
Dr. Garraway is associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, an associate physician at the Brigham and Women’s Hospital, an Institute Member of the Broad Institute of MIT and Harvard, and an investigator of the Howard Hughes Medical Institute.
He is the author of nearly 200 peer-reviewed scientific articles and has received many awards, including the Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from AACR, the New Innovator Award from the NIH, and an Outstanding Investigator Award from the National Cancer Institute.
Dr. Ole Isacson
Dr. Greg LaRosa
Dr. Michael Vincent
Pfizer Appoints Senior officers
Pfizer has appointed Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, as chief scientific officer of the neuroscience research unit and senior VP. Dr. Isacson is a Professor of Neurology at Harvard Medical School, and he continues to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson reports directly to Mikael Dolsten, president of worldwide research and development.
Dr. Isacson received his medical bachelor and doctor of medicine degrees from the University of Lund in Sweden and held a two-year postdoctoral fellowship at Cambridge University in England before joining Harvard in 1989. Over the course of two decades, his lab has become known as one of the most recognized academic research centers for Parkinson’s disease and other neurodegenerative disorders.
Additionally, Pfizer promoted two leading scientists to chief scientific officer positions. Greg LaRosa, Ph.D., was named senior VP and chief scientific officer of the rare disease research Unit. Prior to this role, Dr. LaRosa was head of biology for the rare disease unit. Dr. LaRosa received a Ph.D. from Harvard University in Molecular, Cellular and Developmental Biology and has more than 23 years of experience in rare disease and inflammation drug discovery and development.
Michael Vincent, M.D., Ph.D., was named senior VP and chief scientific officer of the inflammation and immunology research unit. Since joining Pfizer in 2011, Dr. Vincent has held numerous scientific leadership roles, most recently as clinical head for pharmatherapeutics and biotherapeutics. Before joining Pfizer, Dr. Vincent held several positions within medical sciences at Amgen. Dr. Vincent earned his Ph.D. and M.D. degrees from Indiana University. He completed his residency and began his post-doctoral training at the University of Vermont.
GlaxoSmithKline Appoints CEO
Emma Walmsley, currently CEO of GSK’s Consumer Healthcare division, has been appointed GSK CEO and will succeed Andrew Witty as CEO when he retires on March 31, 2017.
GSK Consumer Healthcare, one of the world’s largest consumer health companies, was established in 2015 following completion of GSK’s three-part transaction with Novartis.
Prior to this, Ms. Walmsley was president of GSK Consumer Healthcare and has been a member of GSK’s corporate executive team since 2011. She joined GSK in 2010 from L’Oreal where, over the course of her 17-year career, she held a variety of marketing and general management roles in the UK, Europe, and USA.
Concert Pharmaceuticals Expands Management Team
Concert Pharmaceuticals, a clinical stage biopharmaceutical company focused on applying its DCE platform (deuterated chemical entity platform) to create novel medicines, has expanded its senior management team with the appointment of executives in regulatory affairs and commercial strategy to serve in leadership roles as the company advances its clinical pipeline.
Christine Boisclair has been appointed as VP, regulatory affairs, with primary responsibility for planning and coordinating Concert’s regulatory submissions to the FDA and other regulatory authorities. She replaces Mark Roessel, who recently retired. Ms. Boisclair joins Concert with more than 30 years of regulatory affairs experience in the biopharmaceutical industry across multiple therapeutic areas.
Prior to joining Concert, Ms. Boisclair was VP, regulatory affairs, at Forum Pharmaceuticals.
Scott Weintraub has joined Concert in the newly created position of VP, commercial and product strategy, with responsibilities including overseeing the company’s commercial strategy and market assessments for Concert’s drug candidates and pipeline. Mr. Weintraub joins Concert with more than 17 years of commercial experience in the biopharmaceutical industry, including strategic product assessment, brand positioning, commercial life cycle management, and sales and marketing.
Prior to joining Concert, he was VP of product strategy and marketing at Forum Pharmaceuticals. He also served as senior director of marketing at Sunovion Pharmaceuticals and held sales and marketing positions at AstraZeneca. He holds an M.B.A. in Health Administration and Policy from the University of Miami.
AMAG Pharmaceuticals Appoints Senior VP, Sales and Marketing
AMAG Pharmaceuticals has appointed Tony Casciano to senior VP of sales and marketing for the company’s hematology and oncology business.
Mr. Casciano brings to AMAG more than 15 years of sales and marketing experience and began his career at Sanofi US in 2000. He has advanced through commercial positions of increasing responsibility across a broad range of therapeutic areas, and most recently served as the head of marketing for Sanofi where he led the general medicine division.
Dr. Emmanuel Dulac
Dr. Yvonne Greenstreet
Alnylam Expands and Strengthens Management Team
Alnylam Pharmaceuticals, an RNAi therapeutics company, has announced two key appointments to its senior leadership team. Dr. Yvonne Greenstreet has joined as executive VP, chief operating officer, and Dr. Emmanuel Dulac as senior VP, chief commercial officer. Both Drs. Greenstreet and Dulac offer decades of life-sciences experience in drug development and successfully launching medicines to the market in areas of unmet needs.
Dr. Greenstreet has responsibility for leading the company’s multi-disciplinary product teams from early development through and during commercialization. Additionally, she will be responsible for leading the alliance management team primarily focused on our partnership with Sanofi Genzyme. She brings 25 years of global experience in the pharmaceutical industry, where she has been in senior roles in research and development, strategy, and portfolio management, and has successfully led product development and commercialization teams.
Dr. Greenstreet was previously senior VP and head of medicines development at Pfizer, with accountability for a portfolio that included the immuno-inflammation, vaccines, specialty neuroscience, and rare disease areas.
Dr. Greenstreet holds a bachelor of medicine, bachelor of surgery from the University of Leeds, UK and master of business administration (MBA) from INSEAD, France.
Dr. Dulac is responsible for establishing Alnylam’s global commercial footprint. He leads the development of the global commercial expertise area, building global commercial capabilities, including support of patients post product launch, and building the U.S. commercial operations.
Dr. Dulac brings to Alnylam more than 20 years of international experience in the biotech and pharmaceutical industry. He joins the company from Shire, where he was senior VP, head of the rare disease business Unit. He graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed an MBA from the ESSEC School in Paris.
Dr. Michael Goldberg
Navidea Appoints President and CEO
Navidea Biopharmaceuticals has named Michael Goldberg, M.D., as president and CEO. Dr. Goldberg has been a member of the Navidea board of directors since November 2013, serving as interim CEO from May to October 2014.
Dr. Goldberg most recently was a managing partner of Montaur Capital Partners. Prior to this role, he served as the chairman and CEO of Emisphere Technologies.
Dr. Goldberg graduated from the accelerated six-year combined BS/M.D. program from Rensselaer Polytechnic Institute and the Albany Medical College in 1982, and obtained an MBA from the Graduate School of Business, Columbia University, in 1985.
Navidea is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.
Dr. David King
aTyr Pharma Appoints
Senior VP, Research
aTyr Pharma has appointed David King, Ph.D., senior VP, research. Dr. King leads aTyr’s research and preclinical efforts to advance its Physiocrine biology and support the clinical development of meaningful medicines that target immune and tissue homeostatic pathways for patients with various severe and rare diseases.
Most recently, he served as senior VP of research at Tunitas Therapeutics, where he led the company’s research and preclinical activities. Dr. King received his Ph.D. from the University of Surrey, both in the United Kingdom, and was a Glaxo Group Research postdoctoral fellow.
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators.
EMD Serono Appoints Senior VP, Neurology and Immunology
EMD Serono, the biopharmaceutical business of Merck KGaA, has appointed Craig Millian as senior VP, neurology and immunology. Mr. Millian most recently served as senior VP, head of U.S. fertility and endocrinology at EMD Serono. In this new role, he leads the strategic direction of the company’s U.S. neurology and immunology franchise.
Mr. Millian joined EMD Serono in 2010 to lead the fertility and endocrinology marketing team. He previously served as VP, commercial at Vertex, where he helped design and build the commercial infrastructure, organizational capabilities and go-to-market plans in advance of launching the Vertex product pipeline. Mr. Millian holds an MBA from New York University.
Neon Therapeutics Appoints Oncology Veteran as CEO
Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has appointed Hugh O’Dowd to CEO. Mr. O’Dowd succeeds interim CEO Cary Pfeffer, M.D., a partner at Third Rock Ventures, who is assuming the position of chairman of the company’s board of directors.
Mr. O’Dowd brings experience to Neon Therapeutics in pharmaceutical leadership, moving important oncology therapies from clinical development through commercialization. He joins Neon Therapeutics from Novartis, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy of Novartis Oncology. In this role, he was responsible for global commercialization for the oncology portfolio.
Mr. O’Dowd holds an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Dr. Jane Gross
Aptevo Therapeutics Augments Leadership Team
Aptevo Therapeutics, a biotechnology company focused on developing novel oncology and hematology therapeutics, has announced that Randy Maddux has joined the company as senior VP, operations. Mr. Maddux brings more than 30 years of biopharmaceutical operations experience and has served in key roles supporting the licensure and launch of several successful biopharmaceutical products.
Prior to joining Aptevo, Mr. Maddux served as VP and site director at GlaxoSmithKline.
Mr. Maddux holds an M.B.A. from Duke University.
Additionally, the company has promoted Jane Gross, Ph.D., to the position of senior VP and chief scientific officer. Dr. Gross has a Ph.D. in immunology and more than 25 years of experience in the discovery and development of novel protein therapeutics in autoimmune, infectious disease, and oncology indications. Prior to joining the company, he served as VP of immunology research at ZymoGenetics.
pSivida Implements Leadership Change
pSivida, a leader in the development of sustained release drug delivery products primarily for eye diseases, has appointed Nancy Lurker as its president and CEO and a member of the board of directors.
She replaces Paul Ashton, Ph.D., who has been pSivida’s president and CEO for many years.
From 2008 to 2015, Ms. Lurker served as president and CEO and a director of PDI. She received an M.B.A. from the University of Evansville.
Dr. Christian Dreger
Parexel Appoints Senior VP, Parexel Access and Parexel Consulting
Paraxel, a leading global biopharmaceutical services organization, has appointed Christian Dreger, Ph.D., as senior VP, Parexel Access and Parexel Consulting. Dr. Dreger oversees the strategy and operational management for both businesses. He also serves on Parexel’s business review committee.
Dr. Dreger joins the company from Biogen where he served as VP and head of global commercial operations, biosimilars, in Zug, Switzerland. He has also held international commercial and sales positions of increasing responsibility with billion-dollar P&L and performance management responsibilities at Cubist Pharmaceuticals, AstraZeneca, Schering-Plough, and Roche Pharmaceuticals.
Dr. Dreger holds an MBA and a Ph.D. from the University of Mannheim in Germany and St. Gallen, Switzerland, and an executive MBA from Northwestern University’s Kellogg Graduate School of Management.
ClinTec International Expands
U.S. Management Team
ClinTec International has announced the appointment of Rick Farris, executive VP of operations for North America, as the organization continues to successfully deliver on plans for growth in its clinical research capabilities in the United States.
With almost 30 years experience in the life sciences industry, Mr. Farris joins ClinTec International from Novella Clinical, a Quintiles-owned company, where he held the position of VP in project management for the biopharma and rare disease business unit.
Previously, he served as chief operating officer at Health Decisions, a CRO specializing in female reproductive health, rare disease, diagnostic devices, and oncology.
Dr. Michael Gibertini
INC Research Announces Executive Leadership Promotions
INC Research Holdings, a global Phase I to IV contract research organization, has announced the promotions of Michael Gibertini, Ph.D., and Tara Fitzgerald to key executive leadership roles within the company. Dr. Gibertini, who currently serves as INC Research’s president, clinical development, has been promoted to chief operating officer succeeding Alistair Macdonald, while Ms. Fitzgerald, executive VP, biometrics, has been appointed president, clinical development services.
Ms. Fitzgerald provides global leadership for delivery of the company’s clinical support services, including study start-up, biometrics and safety and pharmacovigilance offerings across Phase I to IV clinical trials, as well the continued growth and expansion of its key value chains. Ms. Fitzgerald joined INC Research in May 2011. She was named to the PharmaVOICE 100 list of the most inspiring people in 2014.
Dr. Gibertini has global responsibility for all operational aspects of INC Research, including clinical operations and clinical development services. He joined INC Research in 2005 and prior to being appointed president, clinical development in 2015 served as president and general manager, CNS. In 2015 Dr. Gibertini was named to the annual PharmaVOICE 100 list of the most inspiring people in the life sciences industry.
Giant Creative/Strategy Makes Promotion
Giant Creative/Strategy, a full-service independent healthcare communications agency on the West Coast, has promoted Kristina Ellis to executive VP, executive creative director as she nears 13 years with the company. In this new role, Ms. Ellis manages Giant’s San Francisco-based creative department, including all copy, art, and experience design functions.
Ms. Ellis has more than 17 years of experience working with leading biotech, pharmaceutical, and medical device companies. In that time, she has helped to launch or re-launch numerous brands within cardiology, dermatology, diabetes, diagnostics, immunology, oncology, and other healthcare categories. She also has worked at Harrison and Star and Williams Labadie.
The Greater Than One Names Partner
The Greater Than One (GTO) Group, a leading communications company, announced the promotion of James Mackie to partner, adding depth to a team of executives designed to improve the customer experience and performance through insight-driven strategic planning and measurement.
Mr. Mackie served as the WPP Global Operations lead for Bayer. He also partnered with Morgan Stanley Wealth Management’s Internet strategy team to create game-changing mobile experiences.
Spectrum Expands Executive Team
Spectrum, an independent communications firm specializing in health science and technology, is continuing its national expansion with the opening of a Chicago office. The firm has appointed David Zitlow, a veteran healthcare communications and marketing executive, to join the firm’s executive leadership team. Mr. Zitlow leads operations in the Midwest and spearheads the firm’s health technology practice. He brings to Spectrum more than 20 years of experience in healthcare marketing and corporate communications. Prior to Spectrum, Mr. Zitlow served on the U.S. leadership team for Burson-Marsteller.
ContextMedia:Health Adds VP
ContextMedia:Health, the leader in patient outcome technologies, has announced that Don Butler has been appointed senior VP of research and development solutions for the life-sciences industry. In this role, Mr. Butler is responsible for building and scaling technology solutions to accelerate clinical trial enrollment and enable new therapy market launches. Mr. Butler most recently served as senior VP of global enterprise sales at Metidata Solutions, where the teams he led were responsible for a significant portion of the firm’s total global revenue. Before his tenure at Metidata, he served as a leader in Oracle’s Health Sciences Global Business Unit.
ERT Enhances Delivery Expertise
ERT, a provider of high-quality patient data collection solutions for use in clinical drug development, has appointed David Elario to executive VP, operations delivery. In the newly created role, Mr. Elario oversees all of ERT’s cross-functional operations, delivering the adaptive problem solving required to swiftly address challenges as they arise. (PV)